Susan Boklage

945 total citations
43 papers, 672 citations indexed

About

Susan Boklage is a scholar working on Surgery, Rheumatology and Economics and Econometrics. According to data from OpenAlex, Susan Boklage has authored 43 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Surgery, 13 papers in Rheumatology and 12 papers in Economics and Econometrics. Recurrent topics in Susan Boklage's work include Rheumatoid Arthritis Research and Therapies (13 papers), Lipoproteins and Cardiovascular Health (10 papers) and Pharmaceutical Economics and Policy (10 papers). Susan Boklage is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (13 papers), Lipoproteins and Cardiovascular Health (10 papers) and Pharmaceutical Economics and Policy (10 papers). Susan Boklage collaborates with scholars based in United States, France and United Kingdom. Susan Boklage's co-authors include Jennifer Pocoski, Vijay N. Joish, Joseph R. Berger, Ronald Preblick, Elisabeth Operschall, Toshio Kimura, Joseph Chiodo, Jorge J. Castillo, Ilya Glezerman and Lois Lamerato and has published in prestigious journals such as CHEST Journal, The American Journal of Cardiology and Annals of Oncology.

In The Last Decade

Susan Boklage

41 papers receiving 652 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan Boklage United States 15 154 139 116 91 88 43 672
İsmail Şimşek Türkiye 15 120 0.8× 96 0.7× 258 2.2× 20 0.2× 111 1.3× 49 677
Sanjeev Balu United States 15 39 0.3× 175 1.3× 23 0.2× 136 1.5× 13 0.1× 48 988
Bogdan Batko Poland 15 36 0.2× 48 0.3× 266 2.3× 52 0.6× 75 0.9× 63 528
Usman Ali Canada 13 116 0.8× 86 0.6× 36 0.3× 18 0.2× 19 0.2× 25 788
Takuya Fukushima Japan 16 98 0.6× 96 0.7× 38 0.3× 14 0.2× 136 1.5× 65 831
Tove Lorenzen Denmark 17 56 0.4× 293 2.1× 386 3.3× 16 0.2× 166 1.9× 35 1.0k
Leen Gilles United States 14 412 2.7× 47 0.3× 89 0.8× 10 0.1× 28 0.3× 15 1.0k
Ju Hyun Lee South Korea 14 113 0.7× 82 0.6× 22 0.2× 27 0.3× 76 0.9× 23 638
Mohd Kashif Siddiqui United States 13 287 1.9× 72 0.5× 41 0.4× 18 0.2× 25 0.3× 23 739

Countries citing papers authored by Susan Boklage

Since Specialization
Citations

This map shows the geographic impact of Susan Boklage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Boklage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Boklage more than expected).

Fields of papers citing papers by Susan Boklage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Boklage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Boklage. The network helps show where Susan Boklage may publish in the future.

Co-authorship network of co-authors of Susan Boklage

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Boklage. A scholar is included among the top collaborators of Susan Boklage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Boklage. Susan Boklage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reck, Martin, Ana Laura Ortega Granados, Filippo de Marinis, et al.. (2023). 1468P Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial. Annals of Oncology. 34. S832–S833. 1 indexed citations
2.
3.
Gabay, Cem, Gerd R Burmester, Vibeke Strand, et al.. (2020). Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes. Arthritis Research & Therapy. 22(1). 70–70. 32 indexed citations
4.
5.
Sullivan, E, et al.. (2020). Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. Rheumatology and Therapy. 7(3). 517–535. 9 indexed citations
6.
Punekar, Rajeshwari, et al.. (2019). Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis.. PubMed. 12(8). 400–409. 1 indexed citations
7.
Burmester, Gerd R, Vibeke Strand, Andrea Rubbert‐Roth, et al.. (2019). Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open. 5(2). e001017–e001017. 9 indexed citations
8.
Rana, Jamal S., Jennifer Y. Liu, Howard H. Moffet, et al.. (2018). Risk of Incident Atherosclerotic Cardiovascular DiseaseEvents by Achieved Atherogenic Lipid Levels Among62,428 Statin-Treated Individuals With Diabetes Mellitus. The American Journal of Cardiology. 122(5). 762–767. 5 indexed citations
9.
Harrison, Teresa N., Ronald D. Scott, T. Craig Cheetham, et al.. (2018). Trends in Statin Use 2009–2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol. Cardiovascular Drugs and Therapy. 32(4). 397–404. 36 indexed citations
10.
Munakata, Julie, Wenhui Wei, Clare Proudfoot, et al.. (2018). Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. ClinicoEconomics and Outcomes Research. Volume 10. 805–819. 3 indexed citations
11.
Chastek, Benjamin, et al.. (2018). SAT0177 Real-world interruptions in janus kinase inhibitor therapy observed among biologic-naÏve and biologic-experienced rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 77. 949–950. 1 indexed citations
12.
Karalis, Dean G., Usha G. Mallya, Ameen Ghannam, et al.. (2018). Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia. The American Journal of Cardiology. 121(10). 1155–1161. 24 indexed citations
13.
Mladsi, Deirdre, et al.. (2017). An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia. Hospital Practice. 45(3). 111–117. 4 indexed citations
14.
Go, Alan S., Dongjie Fan, Sue Hee Sung, et al.. (2017). Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study. American Heart Journal. 194. 25–38. 11 indexed citations
15.
Bellows, Brandon K., et al.. (2017). Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms. Journal of Managed Care & Specialty Pharmacy. 23(9). 926–934. 3 indexed citations
16.
Castillo, Jorge J., Ilya Glezerman, Susan Boklage, et al.. (2016). The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer. 16(1). 564–564. 63 indexed citations
17.
18.
Castillo, Jorge J., Ilya Glezerman, Susan Boklage, et al.. (2015). Incidence and Prognostic Importance of Hyponatremia in a Cohort of Patients With Lung Cancers. CHEST Journal. 148(4). 552A–552A.
19.
Dasta, Joseph F., Sushrut S. Waikar, Lin Xie, et al.. (2015). Patterns of treatment and correction of hyponatremia in intensive care unit patients. Journal of Critical Care. 30(5). 1072–1079. 9 indexed citations
20.
Seal, Brian, Sean D. Sullivan, Scott D. Ramsey, et al.. (2013). Systemic Therapy for Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in Nationally Representative US Claims Database. BioDrugs. 28(2). 229–236. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by İsmail Şimşek Breakdown of academic impact, for papers by Sanjeev Balu Breakdown of academic impact, for papers by Bogdan Batko Breakdown of academic impact, for papers by Usman Ali Breakdown of academic impact, for papers by Takuya Fukushima Breakdown of academic impact, for papers by Tove Lorenzen Breakdown of academic impact, for papers by Leen Gilles Breakdown of academic impact, for papers by Ju Hyun Lee Breakdown of academic impact, for papers by Mohd Kashif Siddiqui
Rankless by CCL
2026